Calamos Advisors LLC Grows Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Calamos Advisors LLC grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 10.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 326,629 shares of the medical equipment provider's stock after acquiring an additional 30,908 shares during the period. Calamos Advisors LLC owned 0.16% of Zimmer Biomet worth $39,751,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. PFG Advisors grew its stake in Zimmer Biomet by 4.6% in the 4th quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider's stock valued at $231,000 after buying an additional 84 shares in the last quarter. Bradley Foster & Sargent Inc. CT boosted its holdings in Zimmer Biomet by 1.3% in the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 6,452 shares of the medical equipment provider's stock valued at $823,000 after purchasing an additional 85 shares during the period. Quent Capital LLC boosted its holdings in Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider's stock valued at $63,000 after purchasing an additional 92 shares during the period. Pinnacle Associates Ltd. boosted its holdings in Zimmer Biomet by 5.0% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider's stock valued at $227,000 after purchasing an additional 97 shares during the period. Finally, Financial Advocates Investment Management boosted its holdings in Zimmer Biomet by 3.8% in the 3rd quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider's stock valued at $295,000 after purchasing an additional 97 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the business's stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Trading Down 1.6 %

Shares of ZBH stock traded down $1.89 during mid-day trading on Thursday, reaching $119.41. The stock had a trading volume of 1,442,258 shares, compared to its average volume of 1,483,553. The stock's 50-day moving average price is $126.39 and its two-hundred day moving average price is $119.10. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $149.25. The firm has a market capitalization of $24.53 billion, a PE ratio of 24.42, a price-to-earnings-growth ratio of 2.24 and a beta of 1.01. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The firm had revenue of $1.94 billion for the quarter, compared to analysts' expectations of $1.93 billion. During the same quarter in the previous year, the company earned $1.88 earnings per share. The company's revenue for the quarter was up 6.3% compared to the same quarter last year. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet's dividend payout ratio is currently 19.63%.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of research analyst reports. Evercore ISI lifted their price objective on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an "in-line" rating in a report on Thursday, April 4th. Canaccord Genuity Group reaffirmed a "hold" rating and set a $130.00 price objective on shares of Zimmer Biomet in a report on Friday, February 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a "neutral" rating in a report on Friday, February 9th. StockNews.com downgraded shares of Zimmer Biomet from a "strong-buy" rating to a "buy" rating in a report on Monday, February 19th. Finally, TheStreet raised shares of Zimmer Biomet from a "c" rating to a "b-" rating in a research note on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $139.39.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.